Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives

Wang, Jingbo; Huang, Xue F.; Li, Furong

doi:10.1186/s40880-019-0387-3

Cited by 61 publications

(53 citation statements)

References 154 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…129 CD103 + DCs alone appear to orchestrate the appropriate Th17 response to fungal infection through production of IL-2 and IL-23. 131,132 Cell-tracking experiments in murine melanoma tumour models show that CD103 + DCs are the only intra-tumoral myeloid cell type able to transport and present intact antigen to tumour-specific CD8 + T cells and their activation was protective against tumour re-challenge. DCs take up necrotic and apoptotic tumour fragments to present to antigen-specific cytotoxic and helper T cells, and are therefore important providers of protective anti-cancer immunity.…”

Section: Dendritic Cellsmentioning

confidence: 99%

“…DCs take up necrotic and apoptotic tumour fragments to present to antigen-specific cytotoxic and helper T cells, and are therefore important providers of protective anti-cancer immunity. 131,132 Cell-tracking experiments in murine melanoma tumour models show that CD103 + DCs are the only intra-tumoral myeloid cell type able to transport and present intact antigen to tumour-specific CD8 + T cells and their activation was protective against tumour re-challenge. 133 However, these cells are rare and transcriptomic analysis of lung cancers and peritumoral tissues from mice demonstrate that the majority of infiltrating myeloid cells are actually CD11b + DCs.…”

Section: Dendritic Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Tissue‐resident innate immunity in the lung

2019

View full text Add to dashboard Cite

The lung is a unique organ that must protect against inhaled pathogens and toxins, without mounting a disproportionate response against harmless particulate matter and without compromising its vital function. Tissue-resident immune cells within the lung provide local immunity and protection from infection but are also responsible for causing disease when dysregulated. There is a growing appreciation of the importance of tissue-resident memory T cells to lung immunity, but non-recirculating, tissue-resident, innate immune cells also exist. These cells provide the first line of defence against pulmonary infection and are essential for co-ordinating the subsequent adaptive response. In this review, we discuss the main lung-resident innate immune subsets and their functions in common pulmonary diseases, such as influenza, bacterial pneumonia, asthma and inflammatory disorders.

show abstract

Section: Dendritic Cellsmentioning

confidence: 99%

Section: Dendritic Cellsmentioning

confidence: 99%

Tissue‐resident innate immunity in the lung

2019

View full text Add to dashboard Cite

show abstract

“…In the NSCLC tumor microenvironment, the landscape of immune cell types is T cells, followed by B cells, macrophages, DCs and natural killer cells [28]. Dendritic cells are specialized antigen-presenting cells that play an important role in the activation of antitumor T lymphocytes [39,40]. The infiltration of T cells generally predicts a better clinical outcomes in patients [41].…”

Section: Figmentioning

confidence: 99%

CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment

et al. 2020

View full text Add to dashboard Cite

Background: Lung cancer is the leading cause of cancer-related mortality globally. Discovering effective biomarkers for early diagnosis and prognosis is important to reduce the mortality rate and ensure efficient therapy for lung cancer patients. C-type lectin domain family 3 member B (CLEC3B) has been reported in various cancers, but its correlation with lung cancer remains elusive. Methods:The GEO, TCGA and Oncomine databases were analyzed to examine the expression of CLEC3B in lung cancer. The CLEC3B mRNA levels in 15 patient tissue samples were detected by real-time PCR and the CLEC3B protein levels in 34 patient tissue samples were detected by immunohistochemistry. A Chi-square test was performed to analyze the correlation of CLEC3B expression and clinicopathological factors. The diagnostic value of CLEC3B was revealed by receiver operating characteristic (ROC) curves. Univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier plots were used to evaluate the prognostic value of CLEC3B in lung cancer. The TIMER database was used to evaluate the correlation of CLEC3B and immune infiltration. Gene set enrichment analysis revealed tumor-associated biological processes related to CLEC3B.Results: CLEC3B is significantly downregulated in lung cancer patients compared with nontumor controls according to database analysis and patient tissue sample detection (p < 0.001). Specifically, CLEC3B is significantly downregulated in stage IA lung cancer patients (p < 0.001) and has a high diagnostic accuracy (area under the receiver operating characteristic curve > 0.9). Moreover, low expression of CLEC3B is related to poor progression-free survival (HR = 0.60, 95% CI 0.49-0.74, p = 8.3e−07) and overall survival (HR = 0.66, 95% CI 0.58-0.75, p = 2.1e−10), indicating it as a risk factor for lung cancer. Multivariate analysis value showed that low expression of CLEC3B may be an independent risk factor for disease-free survival in lung cancer patients (HR = 0.655, 95% CI 0.430-0.996, Cox p = 0.048). In addition, we also investigated the potential role of CLEC3B in tumor-immune interactions and found that CLEC3B might be associated with the immune infiltration and immune activation of lung cancer, especially in squamous cell carcinoma.© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article' s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article'

show abstract

“…These results show that high FGL2 expression is closely related to enhanced CD8 + T cell-mediated antitumor activities. Dendritic cells (DCs) are considered important factors that provide protective immunity against lung adenocarcinoma (Wang, Huang & Li, 2019). Inactive DCs are correlated with the poor prognosis of lung cancer patients.…”

Section: Discussionmentioning

confidence: 99%

FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma

Yuan

Feng

Wang

et al. 2020

PeerJ

View full text Add to dashboard Cite

Lung cancer is the most common malignant tumor, accounting for 25% of cancerrelated deaths and 14% of new cancers worldwide. Lung adenocarcinoma is the most common type of pulmonary cancer. Although there have been some improvements in the traditional therapy of lung cancer, the outcome and prognosis of patients remain poor. Lung cancer is the leading cause of cancer-related deaths worldwide, with 1.8 million new cases being diagnosed each year. Precision medicine based on genetic alterations is considered a new strategy of lung cancer treatment that requires highly specific biomarkers for precision diagnosis and treatment. Fibrinogen-like protein 2 (FGL2) plays important roles in both innate and adaptive immunity. However, the diagnostic value of FGL2 in lung cancer is largely unknown. In this study, we systematically investigated the expression profile and potential functions of FGL2 in lung adenocarcinoma. We used the TCGA and Oncomine datasets to compare the FGL2 expression levels between lung adenocarcinoma and adjacent normal tissues. We utilized the GEPIA, PrognoScan and Kaplan-Meier plotter databases to analyze the relationship between FGL2 expression and the survival of lung adenocarcinoma patients. Then, we investigated the potential roles of FGL2 in lung adenocarcinoma with the TIMER database and functional enrichment analyses. We found that FGL2 expression was significantly lower in lung adenocarcinoma tissue compared with adjacent normal tissue. A high expression level of FGL2 was correlated with better prognostic outcomes of lung adenocarcinoma patients, including overall survival and progression-free survival. FGL2 was positively correlated with the infiltration of immune cells, including dendritic cells, CD8 + T cells, macrophages, B cells, and CD4 + T cells, in lung adenocarcinoma. Functional enrichment analyses also showed that a high expression level of FGL2 was positively correlated with enhanced T cell activities, especially CD8 + T cell activation. Thus, we propose that high FGL2 expression, which is positively associated with enhanced antitumor activities mediated by T cells, is a beneficial marker for lung adenocarcinoma treatment outcomes. . 2020. FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma. PeerJ 8:e8654 http://doi.BE, Golub TR, Sugarbaker DJ, Meyerson M. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J. 2013. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. Journal T. 2013. Soluble FGL2 induced by tumor necrosis factor-α and interferon-γ in CD4+ T cells through MAPK pathway in human renal allograft acute rejection.

show abstract

Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives

Cited by 61 publications

References 154 publications

Tissue‐resident innate immunity in the lung

Tissue‐resident innate immunity in the lung

CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment

FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma

Contact Info

Product

Resources

About